Physician profile
Joni Abramczyk
NPI 1003365198
$5,187.09
in general payments reported to CMS, 2019-2025
33 companies · $540 in 2025
The $540 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,386 · 2022: $1,412 · 2023: $1,037 · 2024: $812 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,388.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $953.52 | 2021-2025 | Proclaim, Eterna, Prodigy |
| Abbvie INC. | $866.75 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Collegium Pharmaceutical, INC. | $863.60 | 2021-2025 | Xtampza, Belbuca |
| Medtronic, INC. | $419.51 | 2021-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $222.84 | 2021-2025 | Relistor |
| Pfizer INC. | $202.48 | 2021-2025 | |
| Vertos Medical, INC. | $188.85 | 2021-2024 | Mild Device Kit |
| Grt US Holding, INC. | $169.96 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $130.45 | 2021 | |
| Nevro Corp. | $123.88 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $116.38 | 2022 | |
| Curonix LLC | $102.15 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Boston Scientific Corporation | $97.45 | 2021 | |
| Averitas Pharma INC. | $87.50 | 2023-2025 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $84.53 | 2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $60.81 | 2021 | |
| Stimwave Technologies Incorporated | $56.79 | 2021 | |
| Ibsa Pharma INC. | $56.63 | 2022-2023 | Tirosint, Licart |
| Lilly USA, LLC | $54.38 | 2021-2023 | Reyvow, Emgality |
| Lundbeck LLC | $48.80 | 2024 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $32.78 | 2021 | |
| Amgen INC. | $28.52 | 2021 | |
| Tersera Therapeutics LLC | $27.54 | 2022 | |
| Saluda Medical Americas, INC. | $27.53 | 2024-2025 | Evoke |
| Mdd US Operations, LLC | $27.08 | 2022 | |
| Scilex Pharmaceuticals INC. | $25.48 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $20.39 | 2025 | Xeomin |
| Stryker Corporation | $19.18 | 2024 | Mild Device Kit |
| Supernus Pharmaceuticals, INC. | $16.66 | 2021 | |
| Valinor Pharma, LLC | $15.62 | 2025 | Movantik |
| Amneal Pharmaceuticals LLC | $13.59 | 2023 | Lyvispah |
| Depuy Synthes Sales INC. | $13.46 | 2025 | Monovisc, Orthovisc |
| Allergan, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joni Abramczyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.